Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines
Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines
复制标题
DOI：
10.1016/j.otohns.2007.06.736
复制
发表时间：
2007-11-01
影响因子：
3.4
通讯作者：
Rosenthal, Eben L.
中科院分区：
文献类型：
--
作者：
Withrow, Kirk P.;Gleysteen, John P.;Rosenthal, Eben L.
目的：本研究的目的是确定吲哚菁绿色（ICG）的抗表皮生长因子受体抗体（西妥昔单抗）的图像头颈cancer.Study设计：小鼠（n = 3）注射非共轭ICG和成像在100秒的时间间隔为1000秒，以评估成像特性。然后将SCC-1细胞异种移植的小鼠（n = 10）全身注射与吲哚菁绿色缀合的西妥昔单抗，并在72小时内成像。为了评估的敏感性和特异性，异种移植肿瘤进行次全切除术，然后通过荧光立体显微镜和组织学确认残留疾病进行评估。荧光与西妥昔单抗-ICG的给定剂量之间存在直接关系。在次全切除术后，我们发现荧光检测的敏感性为78.4%，特异性为96%.CONCLUSION：本研究为西妥昔单抗在评估手术切缘方面的进一步临床前研究提供了证据，但与ICG的联系缺乏临床应用的敏感性。(C)2007年美国耳鼻咽喉头颈外科学会基金会。All rights reserved.
OBJECTIVE: The aim of this study is to determine the efficacy of indocyanine green (ICG) conjugated to antiepidermal growth factor receptor antibody (cetuximab) to image head and neck cancer.STUDY DESIGN: Mice (n = 3) were injected with unconjugated ICG and imaged at 100-second intervals for a total of 1000 seconds to assess imaging characteristics. Mice (n = 10) xenografted with SCC-1 cells were then systemically injected with cetuximab conjugated to indocyanine green and imaged over a 72-hour period. To assess the sensitivity and specificity, xenografted tumors underwent subtotal resections and then were assessed for residual disease by fluorescence stereomicroscopy and confirmed by histology.RESULTS: Tumors demonstrated excellent fluorescence 24 hours after injection of cetuximab-ICG. There was a direct relationship between fluorescence and the given dose of cetuximab-ICG. Following subtotal resection, we found fluorescence correlated with a sensitivity of 78.4% and specificity of 96%.CONCLUSIONS: This study provides evidence that supports further preclinical investigation of cetuximab in the evaluation of surgical margins, but linkage to ICG lacks the sensitivity for use in a clinical setting.(C) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.